๐Ÿ”ฌDeep Research

BMEA โ€” Biomea Fusion Inc ยท catalysts, narrative & risks

ยท18 sourcesBMEA forecast โ†’

Biomea Fusion, Inc. (Nasdaq: BMEA) โ€” As of 2026-10-12

Background / positioning

Biomea Fusion is a clinical-stage diabetes and obesity medicines company based in San Carlos, California, focused on oral small-molecule therapies, notably icovamenib (formerly BMF-219, an oral covalent menin inhibitor) and BMF-650 for obesity [2], [6], [13]. It is a micro-cap with a market cap of roughly $102.9M, no revenue, and a stock that has traded between ~$0.87 and $2.24 over the past year [10], [13], [15].

Recent catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’